CA2088671A1 - Utilisation d'inhibiteurs de proteinases dependant de l'ion ca2+ dans les preparations pharmaceutiues - Google Patents
Utilisation d'inhibiteurs de proteinases dependant de l'ion ca2+ dans les preparations pharmaceutiuesInfo
- Publication number
- CA2088671A1 CA2088671A1 CA2088671A CA2088671A CA2088671A1 CA 2088671 A1 CA2088671 A1 CA 2088671A1 CA 2088671 A CA2088671 A CA 2088671A CA 2088671 A CA2088671 A CA 2088671A CA 2088671 A1 CA2088671 A1 CA 2088671A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitors
- therapy
- contraception
- canps
- neutral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000007935 neutral effect Effects 0.000 abstract 2
- 235000019419 proteases Nutrition 0.000 abstract 2
- 239000000758 substrate Substances 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 102000004142 Trypsin Human genes 0.000 abstract 1
- 108090000631 Trypsin Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 230000022534 cell killing Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 235000019833 protease Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012588 trypsin Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GR91100238 | 1991-06-03 | ||
| GR910100238 | 1991-06-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2088671A1 true CA2088671A1 (fr) | 1992-12-04 |
| CA2088671C CA2088671C (fr) | 1997-01-14 |
Family
ID=10940713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002088671A Expired - Fee Related CA2088671C (fr) | 1991-06-03 | 1992-06-02 | Utilisation d'inhibiteurs de proteinases dependant de l'ion ca2+ dans les preparations pharmaceutiues |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0549742B1 (fr) |
| JP (1) | JP3703828B2 (fr) |
| AT (1) | ATE263574T1 (fr) |
| AU (1) | AU646961B2 (fr) |
| CA (1) | CA2088671C (fr) |
| DE (1) | DE69233337T2 (fr) |
| DK (1) | DK0549742T3 (fr) |
| ES (1) | ES2215162T3 (fr) |
| GR (1) | GR1001044B (fr) |
| IL (1) | IL102079A (fr) |
| NO (1) | NO930305L (fr) |
| NZ (1) | NZ243003A (fr) |
| PT (1) | PT100560A (fr) |
| WO (1) | WO1992021373A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU681350B2 (en) * | 1992-09-09 | 1997-08-28 | Amgen, Inc. | Inhibitiion of retrovirus infection |
| US5607831A (en) * | 1993-03-25 | 1997-03-04 | The United States Of America As Represented By The Department Of Health And Human Services | In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death |
| EP0626178A1 (fr) * | 1993-05-17 | 1994-11-30 | Ciba-Geigy Ag | Utilisation d'inhibiteurs de la protease du VIH dans le traitement des maladies tumorales |
| US20030060435A1 (en) | 1994-05-31 | 2003-03-27 | Serge Carillo | Method of cancer treatment by p53 protein control |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8815962D0 (en) * | 1988-07-05 | 1988-08-10 | Univ London | Pharmaceutical preparation & method for promoting reinnervation of muscle fibers |
-
1991
- 1991-06-03 GR GR910100238A patent/GR1001044B/el not_active IP Right Cessation
-
1992
- 1992-06-01 PT PT100560A patent/PT100560A/pt not_active Application Discontinuation
- 1992-06-02 CA CA002088671A patent/CA2088671C/fr not_active Expired - Fee Related
- 1992-06-02 EP EP92911432A patent/EP0549742B1/fr not_active Expired - Lifetime
- 1992-06-02 JP JP51122392A patent/JP3703828B2/ja not_active Expired - Fee Related
- 1992-06-02 WO PCT/EP1992/001223 patent/WO1992021373A1/fr active IP Right Grant
- 1992-06-02 ES ES92911432T patent/ES2215162T3/es not_active Expired - Lifetime
- 1992-06-02 DE DE69233337T patent/DE69233337T2/de not_active Expired - Fee Related
- 1992-06-02 DK DK92911432T patent/DK0549742T3/da active
- 1992-06-02 AU AU19073/92A patent/AU646961B2/en not_active Ceased
- 1992-06-02 IL IL10207992A patent/IL102079A/en not_active IP Right Cessation
- 1992-06-02 AT AT92911432T patent/ATE263574T1/de not_active IP Right Cessation
- 1992-06-03 NZ NZ243003A patent/NZ243003A/en not_active IP Right Cessation
-
1993
- 1993-01-29 NO NO93930305A patent/NO930305L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GR1001044B (el) | 1993-04-28 |
| AU1907392A (en) | 1993-01-08 |
| CA2088671C (fr) | 1997-01-14 |
| EP0549742A1 (fr) | 1993-07-07 |
| EP0549742B1 (fr) | 2004-04-07 |
| WO1992021373A1 (fr) | 1992-12-10 |
| PT100560A (pt) | 1993-07-30 |
| ATE263574T1 (de) | 2004-04-15 |
| DK0549742T3 (da) | 2004-07-26 |
| NO930305D0 (no) | 1993-01-29 |
| JP3703828B2 (ja) | 2005-10-05 |
| AU646961B2 (en) | 1994-03-10 |
| DE69233337D1 (de) | 2004-05-13 |
| IL102079A (en) | 1996-10-16 |
| ES2215162T3 (es) | 2004-10-01 |
| NZ243003A (en) | 1997-07-27 |
| DE69233337T2 (de) | 2005-05-04 |
| JPH06502188A (ja) | 1994-03-10 |
| NO930305L (no) | 1993-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO308794B1 (no) | Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse | |
| BG101118A (en) | Therapeutical compounds | |
| NO971889D0 (no) | Forbindelser og sammensetninger for levering av aktive midler | |
| BR0316234A (pt) | Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos | |
| EA199901031A1 (ru) | Производные бензимидазола | |
| ATE147981T1 (de) | Verabreichung von lamotrigin zur behandlung von neuro-aids | |
| PL294701A1 (fr) | ||
| PT1149910E (pt) | Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus | |
| ATE215952T1 (de) | Hiv-proteaseinhibitoren | |
| DE58909850D1 (de) | Arzneimittel zur behandlung von krebs, aids und viruserkrankungen | |
| CA2088671A1 (fr) | Utilisation d'inhibiteurs de proteinases dependant de l'ion ca2+ dans les preparations pharmaceutiues | |
| BR0110396A (pt) | Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia | |
| CA2078544A1 (fr) | Methode et compositions pour le traitement de lesions | |
| Sakamoto et al. | Maintenance of mouse bone collagenase activity in the presence of serum protein by addition of trypsin | |
| AU2135688A (en) | Pharmaceutical composition for preventing and treating bacterial or viral diseases | |
| NO20050067L (no) | Pegylert T1249 polypeptid | |
| ATE91237T1 (de) | Kombinationen von nekrose-tumor-faktoren und entzuendungshemmenden mitteln fuer die behandlung von boesartigen und nicht boesartigen erkrankungen. | |
| IE840977L (en) | Pharmaceutical preparations | |
| RU95109909A (ru) | Способ ингибирования ретровирусной инфекции, ингибитор протеазы, кодирующая его нуклеиновая кислота и способ рекомбинантного продуцирования серинового ингибитора | |
| AU2396900A (en) | Treatment and prevention of hiv and other viral infections | |
| MY111630A (en) | Amino acid derivatives. | |
| GEP19991605B (en) | Inhibitor, Its Obtaining and Use | |
| UA42462A (uk) | Бромідний комплекс міді (іі) та кобальту (ііі) з діетаноламіном, що виявляє протипухлинну дію | |
| MX9707811A (es) | Una composicion farmaceutica que contiene n-clorofenilcarbamatos, n-clorofeniltiocarbamatos y derivados de n-fosfonoglicina para inhibir el crecimiento de canceres y virus en mamiferos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |